More patients across the world lowering 'bad' cholesterol – Further Marketing for Statins?
Posted Jun 23 2009 10:41pm
Is a plan to somehow get everyone on a statin drug? As mentioned there are other ways of lowering cholesterol as well. As obesity has increased I tend to believe so has the use of statins. In another recent report it was noted that statins can protect against Alzheimer's disease.
The Jupiter report just never seems to die down. Recently there was the report and opinion listed below that we should all take a combination blood pressure/statin pill.
The best evaluation I saw on the web was from the Happy Hospitalist, he makes sense to me with regards to one statin, Crestor. With reports surfacing about physicians not being truthful on some of the reports and items published in journals, I’m just a bit leery on jumping on this bandwagon. BD
All Americans will now get Crestor to reduce their CRP to reduce their chances of developing heart disease.
All Americans Will now get lisinopril to prevent the proteinuria they will get from their diabetes they get from Crestor
All Americans will now take metformin to treat the diabetes they developed while taking Crestor
All Americans will now take Lyrica to prophylax for the the neuropathic pain they will get from developing diabetes while taking Crestor.
All Americans will now take an aspirin to reduce the risk of developing a stroke from the diabetes they got from taking Crestor.
All Americans will now take prilosec to reduce the risk of developing an ulcer from the aspirin they were taking to reduce the risk of stroke due to the diabetes they developed while taking Crestor to reduce their asymptomatic CRP level.
All Americans will now take carvedilol to reduce the risk of death from the coronary artery disease they developed as a result of the diabetes they developed as a result of the Crestor they were taking to reduce their CRP to reduce their chances of developing coronary artery disease
The percentage of patients lowering their elevated "bad" cholesterol to within target levels nearly doubled in the last decade, according to a multi-national survey reported in Circulation: Journal of the American Heart Association.
In the Lipid Treatment Assessment Project (L-TAP) 2 — a survey of nearly 10,000 patients (average age 62) from nine countries undergoing cholesterol-lowering and management efforts — researchers found that:
The number of patients successfully reaching their respective low-density lipoprotein (LDL) levels rose from 38 percent to 73 percent over the last 10 years.
Among high-risk patients, 67 percent reached established goal levels.
Only 30 percent of very high risk patients — those with existing coronary artery disease and two or more other risk factors such as obesity, diabetes and smoking — successfully reached their LDL target of 70 milligrams per deciliter (mg/dL) or less.
LDL is known as "bad" cholesterol because it's associated with increased cardiovascular risk. Researchers found that 75 percent of the patients surveyed were taking a statin drug (atorvastatin, simvastatin, rosuvastatin or pravastatin). The median duration of therapy was two years. Others were treated with fibrates, ezetimbe or lifestyle changes such as diet and exercise alone.